TRUEPILOT
Dead · Refused DEAD/APPLICATION/Refused/Dismissed or Invalidated
What this record means
The record shows that the mark “TRUEPILOT” is dead; it was abandoned because the owner, Bristol‑Myers Squibb Company, did not file a Statement of Use or an Extension Request after the Notice of Allowance was issued. The mark was filed on August 7, 2006 and was published for opposition on August 28, 2007, with the Notice of Allowance issued on November 20, 2007. The goods covered are pharmaceutical preparations for human use, including treatments for obesity, diabetes, cardiovascular diseases, and many other conditions, as listed in Class 005. A similar name used in the same or closely related pharmaceutical field would raise the closest record‑based concern, while use in unrelated industries would be farther from the scope shown. The record does not give the owner control over every use of the wording. No enforcement actions, oppositions, or cancellations appear in the supplied history. The latest meaningful event is the abandonment notice on August 11, 2008. For someone considering a similar name, the abandoned status means the mark is no longer protected, but the detailed pharmaceutical scope still signals a potential concern if used in that area.
Informational only - not legal advice.Mark Trademark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Intent-to-Use (§1(b)). |
| Status | Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page. |
Key dates
| Application filed | Aug 07, 2006 |
| Published for opposition | Aug 28, 2007 |
| Notice of Allowance | Nov 20, 2007 |
| Status date | May 21, 2008 |
Goods & services
Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, and pharmaceutical antibodies; syringes filled with a pharmaceutical product for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, antibiotics, anti-fungals, anti-virals, immunosuppressants and pharmaceutical antibodies
Owner & representation
| Owner | Bristol-Myers Squibb Company |
| Address | 345 Park Avenue, New York, NEW YORK UNITED STATES 10154 |
| Entity | CORPORATION - organized in DELAWARE |
| Attorney of record | Nadine P. Flynn |
| Correspondent | |
| Correspondent phone | 2********1 |